Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2007

View Archived Issues

Synergistic effects of triple antiangiogenic therapy in preclinical models of neovascularization

PRX-302 shows promise for prostate cancer

Intravenous cannabinor shows no efficacy benefit in capsaicin-induced pain

New phase II study for PEP-005 Topical in actinic keratosis

FTC clears Hospira's acquisition of Mayne Pharma

Tentative approval for Barr's generic version of Kytril

Bionovo opens pharmacokinetics study of MF-101

Nalbuphine ER begins phase I safety study for pain

Bayer Schering signs agreement for novel neurodegenerative imaging compounds

MBP-8298 cleared to begin U.S. phase III study in secondary progressive MS

Recent Janssen and Aska patents report new therapeutic agents for urological disorders

Recent Merck, Ambrilia and AnorMED patents disclose novel therapeutics for HIV infection

Safety data from the STAR study presented

No benefit of adding bevacizumab to standard therapy in pancreatic cancer

New treatment options for cardiovascular disorders imparted in recent patents

Addition of bevacizumab to chemotherapy improves progression-free survival in MCRC patients

Final results from the ACTS-GC trial announced

AnGes inlicenses Naglazyme for Japan

Iomai awarded contract for adjuvant patch for use with pandemic influenza vaccine

Novel orally active oxytocin receptor antagonist profiled at GlaxoSmithKline

Novartis and Mochida to copromote Diovan in Japan

Johns Hopkins team reports favorable data on pancreatic cancer vaccine

FDA grants orphan drug status for droxidopa in neurogenic orthostatic hypotension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...